#ESMORareCancers26: ARCAGEN highlights a gap between molecular profiling and treatment in advanced #RareCancers. Among patients with clinically actionable alterations, only 15% received matched targeted therapy or #immunotherapy.
#ESMODailyReporter 📌 https://ow.ly/bjjH50YFB8j
👉 Stay at the cutting edge of rare cancers
All authorised congress sessions from ESMO Sarcoma and Rare Cancers 2026 are now on #OncologyPRO for registered delegates & ESMO members
Explore the science anytime, anywhere
🔗 https://ow.ly/nJlY50YuMvG
#ESMORareCancers26 #esmomeetings
Some undifferentiated #sarcomas appear to be responsive to #immunotherapy but reliable #biomarkers are needed. @pawelsobczuk.bsky.social
explains more in his Opinion piece in the #ESMODailyReporter ➡️https://ow.ly/Gr0t50YtqJj
#ESMORareCancers26
Honoured for having the opportunity to present some of our work Dr Nagaraju Prof Aziz on #appendixcancer at #ESMORareCancers26
Glad to see you back Dr Strach and Prof Deraco
Thank you Drs Shiu and Wyrwicz for moderating the session!
@myesmo.bsky.social
#ESMORareCancers26: Preliminary data with the DR5 agonist, ozekibart, added to chemotherapy indicate robust activity and a manageable safety profile in relapsed/refractory #EwingSarcoma. Learn more ➡️https://ow.ly/fR7Z50Ytqq5
#ESMODailyReporter
#ESMORareCancers26: Adding first-line #immunotherapy to methotrexate improved response in patients with low-risk gestational trophoblastic neoplasia (#GTN) but must be balanced with safety and fertility considerations. Check out the #ESMODailyReporter: https://ow.ly/8jpy50YsKVz
🏆 Congratulations to the #ESMOMeritAward recipients at #ESMORareCancers26
These young researchers were recognised for the scientific merit of their abstracts.
🔗https://ow.ly/CPuX50YsfWE
#RareCancers #Oncology #Sarcoma
💪 We continue our strong EORTC presence at #ESMORareCancers26, sharing new evidence on QoL, molecular profiling and treatment innovation in rare cancers.
Tomorrow, look out for Tetsuya Sekita’s poster on surgical quality in retroperitoneal liposarcoma.
#EORTC #RareCancers
This morning at #ESMORareCancers26, EORTC President Prof. Winette T. van der Graaf presented on advancing interventional research, noting:
“EORTC contributes to the EU Cancer Mission Forum for Rare Cancers, working towards a pan-European patient-centred solution.”
#EUHealth #CancerResearch
In #RareCancers, guidelines are vital to bring together scattered expertise. A recent EURACAN survey highlights a high uptake of recommendations from oncologists, potentially leading to improved patients’ survival.
#ESMORareCancers26 #ESMODailyReporter
📌 https://ow.ly/nooJ50YsIQ9
🙌 Welcome to the ESMO Sarcoma and Rare Cancers Congress 2026!
12–14 March, Lugano.
Hope, care and action drive breakthroughs.
Thank you for being part of this progress.
#ESMORareCancers26 #esmomeetings
🔗 https://ow.ly/B9qr50YsINg
📣 All accepted Proffered Paper, Mini Oral, Poster and ePoster abstracts for #ESMORareCancers26 are now online!
Dive into the latest research advancing sarcoma and rare cancers care.
🔗 https://ow.ly/GQI450Yp3SR
#esmomeetings
👉 Prof. David Thomas, Sydney, Australia, ESMO Sarcoma and Rare Cancers 2026 Scientific Co-Chair, invites you to join a gathering where rare cancers research comes together to drive real-world impact. Register now!
🔗 https://ow.ly/PCAR50Yclm5
#ESMORareCancers26 #esmomeetings
👉 Prof. Eva Tiensuu Janson, Uppsala, Sweden, ESMO Sarcoma and Rare Cancers 2026 Scientific Co-Chair, invites you to meet peers and experts shaping the future of rare cancer care. ⏰ Register by 11 Feb and save! #ESMORareCancers26 #esmomeetings
🔗 https://ow.ly/xX5150Y5hzj
📣 #PatientAdvocate Workshops at #ESMORareCancers26
13–14 Mar
✅ #HTA & patient input
✅ Rare cancer research
✅ Care via reference centres, guidelines & outcomes
✔️ Registration required | ESMO Advocates: reduced fee, late 11 Feb
❌ No travel grants
🔗 https://ow.ly/afrN50Y494L
👉 Hear from leading voices on why ESMO Sarcoma and Rare Cancers 2026 is essential for anyone working on rare cancers and sarcomas.
⏰ Early registration closes tomorrow - 14 January—secure your seat now! #ESMORareCancers26
🔗 buff.ly/fEWQ3Nw
👉 Don’t miss ESMO Sarcoma and Rare Cancers 2026, from 12 to 14 March 2026 in Lugano. Hear top experts discuss rare tumours and drive global collaboration.
⏰ Early bird rates end 14 January—secure your seat now! #ESMORareCancers26, #esmomeetings
🔗 buff.ly/vMkriyK
⏰ Tomorrow, 9 December, is the abstract deadline for ESMO Sarcoma and Rare Cancers 2026.
👉 The Scientific Co-Chairs highlight how your submission can fuel research progress, spark collaboration & support public health. Act now! #ESMORareCancers26 #esmomeetings
🔗 buff.ly/jqgNWSo
📣 Registration is open for ESMO Sarcoma and Rare Cancers 2026! Join us 12–14 March in Lugano. ⏰ Early rates end 14 Jan 2026 23:59 CET – secure your seat now! #ESMORareCancers26 #esmomeetings
🔗 https://ow.ly/lQ9U50XocB5
🔬 Ready to push the boundaries of sarcoma research?
⏰ Submit your abstract by 9 December for #ESMORareCancers26, 12–14 March 2026 in Lugano. Together, we shape the future of rare cancers. #esmomeetings
🔗 buff.ly/YTSuDK0
👉 Showcase your rare cancer research! #ESMORareCancers26 Chairs Prof. David Thomas, Prof. Eva Tiensuu Janson & Dr. Claudia Valverde highlight why abstracts matter: visibility, expert feedback & networking.
⏰ Submit by 9 Dec 2025.
🔗 buff.ly/0MGWMsn
📣 Abstract submission is OPEN for the ESMO Sarcoma and Rare Cancers Congress 2026! 12–14 March 2026, Lugano, Switzerland
⏰ Abstracts deadline: 9 December, 21:00 CET
👉 Bring your research to the forefront of oncology at this leading international forum. #ESMORareCancers26
🔗 buff.ly/L8mwwmk
